A Short, All-oral Regimen for Pre-extensively Drug-resistant Tuberculosis: A Multicenter Open-label Single-arm Study
Clinical Infectious Diseases · 04.02.2026 · 81 (6) · e502-e509
DOI: 10.1093/cid/ciaf351 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 08.07.2025. Verfasst von Yang Li und 24 weiteren Autor:innen. Beteiligte Einrichtung: National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Antitubercular Agents, Extensively Drug-Resistant Tuberculosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Clinical Research and Cultivation Project of Shanghai ShenKang Hospital Development Centre, Shanghai Municipal Science and Technology, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Preextensively drug-resistant tuberculosis (pre-XDR-TB) remains a critical public health threat because of limited treatment options and significant disease burden. Existing regimens have shown high success rates but are often inaccessible globally, necessitating alternative options.
Methods
This study was an open-label, multicenter, single-arm study conducted in China to evaluate the efficacy and safety of a 6- to 9-month oral regimen. Eligible participants, aged 18–70 years with pulmonary pre-XDR-TB received a regimen of bedaquiline, linezolid, cycloserine, pyrazinamide, and/or clofazimine. Pyrazinamide was either replaced with clofazimine or retained without clofazimine based on molecular susceptibility results. The primary efficacy endpoint was the percentage of participants with a favorable outcome at 84 weeks after treatment initiation in the modified intention-to-treat population.
Results
A total of 89 patients with pre-XDR-TB were enrolled. At 84 weeks after treatment initiation in the modified intention-to-treat analysis, 62 of 80 participants (77.5%; 95% confidence interval, 67.2–85.3) had favorable outcomes. The 18 unfavorable outcomes were 5 regimen discontinuations or changes (6.3%; 4 due to adverse events and 1 decided by the local investigator), 4 bacteriological failures (5.0%), 4 withdrawals of consent (5.0%), 3 deaths (3.8%), and 2 losses to follow-up (2.5%). No relapse was reported after the end of treatment. Adverse events of grade 3 or higher were observed in 59.1% of participants, with QTc prolongation being the most frequently reported.
Conclusions
This study demonstrated that an all-oral, bedaquiline-based regimen provides a viable treatment option for patients with pre-XDR-TB, achieving acceptable efficacy and manageable safety profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
- Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Sci-Tech Inno Center for Infection & Immunity, Shanghai, China.
- Department of Tuberculosis, Guiyang Public Health Clinical Center, Guiyang, Guizhou, China.
- Tuberculosis Diagnosis and Treatment Center, Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China.
- 6th Medical Department, Hunan Chest Hospital, Changsha, Hunan, China.
- Tuberculosis Prevention and Treatment Hospital in Shaanxi Province, Xi'an, Shaanxi, China.
ORCID-Profile: Yuqing Wu
Förderung
- Clinical Research and Cultivation Project of Shanghai ShenKang Hospital Development Centre
- Shanghai Municipal Science and Technology
- National Natural Science Foundation of China
- Shanghai's three-year plan for Public Health Talent Training
- Independent Project of Shanghai Sci-Tech Inno Center for Infection & Immunity
Zitieren
APA
Li, Y., Zhang, Y., Song, L., Cai, C., Chen, Y., Yi, H., Wu, Q., Qian, Y., Yu, H., Lan, Y., Shi, J., Huang, Y., Zhang, Y., Feng, S., Xiao, M., Wang, J., Li, Y., Wang, H., He, Z., …, & Zhang, W. (2026). A Short, All-oral Regimen for Pre-extensively Drug-resistant Tuberculosis: A Multicenter Open-label Single-arm Study. Clinical Infectious Diseases, 81(6), e502-e509. https://doi.org/10.1093/cid/ciaf351
Vancouver
Li Y, Zhang Y, Song L, Cai C, Chen Y, Yi H, et al. A Short, All-oral Regimen for Pre-extensively Drug-resistant Tuberculosis: A Multicenter Open-label Single-arm Study. Clinical Infectious Diseases. 2026;81(6):e502-e509. doi:10.1093/cid/ciaf351
BibTeX
@article{Li2026,
author = {Li, Yang and Zhang, Yilin and Song, Lingyun and Cai, Cui and Chen, Yuanyuan and Yi, Hengzhong and Wu, Qianhong and Qian, Yuan and Yu, Hongying and Lan, Yuanbo and Shi, Jichan and Huang, Ya and Zhang, Yungui and Feng, Shun and Xiao, Mingying and Wang, Jing and Li, Yiming and Wang, Hua and He, Zebao and Liu, Haiqing and Zhang, Yena and Zhou, Yong and Wu, Yuqing and Sun, Feng and Zhang, Wenhong},
title = {A Short, All-oral Regimen for Pre-extensively Drug-resistant Tuberculosis: A Multicenter Open-label Single-arm Study},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {81},
number = {6},
pages = {e502--e509},
doi = {10.1093/cid/ciaf351}
}
EUVIMED